期刊
DIABETES RESEARCH AND CLINICAL PRACTICE
卷 79, 期 3, 页码 453-460出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.diabres.2007.11.014
关键词
metformin; oral glucose tolerance testing; pioglitazone; sulfonylurea; Type 2 diabetes
Aim: We report the effectiveness of the thiazolidinedione, pioglitazone, as add-on medication to metformin or sulfonylurea in reducing post-load serum glucose levels, as assessed by 3-h oral glucose tolerance testing (OGTT). Methods: Adult patients with Type 2 diabetes took part in one of two large-scale, 2-year clinical trials. One study compared pioglitazone treatment as add-on to failing metformin therapy (N = 317) with add-on gliclazide treatment to metformin (N = 313). The other study compared combination therapy with pioglitazone added to existing failing sulfonylurea therapy (N = 319) with metformin treatment in addition to sulfonylurea (N = 320). HbA(1c), and fasting plasma glucose concentrations were measured at baseline and throughout the study and at the final visit at week 104. At selected centers (N = 299 patients), a 3-h OGTT was performed at baseline and at week 104. Results: At week 104, mean HbA(1c) reduction from baseline was 0.89% for pioglitazone and 0.77% for gliclazide addition to metformin (p = 0.200) and 1.03% with pioglitazone and 1.16% with metformin addition to sulfonylurea (p = 0.173) in the total patient cohort. In the 299 patients who underwent OGTT, 2 years of treatment with pioglitazone, whether added to existing metformin or sulfonylurea medication, resulted in decreases in glucose excursions after an oral glucose load without increasing post-load serum insulin concentrations. In contrast, gliclazide in combination with metformin therapy caused increases in both post-load serum glucose and insulin excursions after 2 years, whereas metformin add-on to sulfonylurea did not have a significant effect on post-load serum glucose concentrations and resulted in an increase in insulin levels. Conclusions: There were no significant differences in HbA(1c) levels between groups. However, 2-year treatment with pioglitazone as an add-on to either failing metformin or sulfonylurea therapy improved post-load glucose excursions without affecting insulin secretion. In contrast, glucose excursions were not improved by gliclazide or metformin add-on therapy, despite increases in post-load insulin levels. These data suggest that pioglitazone reduces peripheral insulin resistance via mechanisms different from those of metformin. (C) 2007 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据